- Home
- SLSN vs NYXH Comparison
SLSN vs NYXH Comparison
Compare SLSN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSN
- NYXH
- Stock Information
- Founded
- SLSN 1989
- NYXH 2009
- Country
- SLSN United States
- NYXH Belgium
- Employees
- SLSN N/A
- NYXH N/A
- Industry
- SLSN
- NYXH Medical/Dental Instruments
- Sector
- SLSN
- NYXH Health Care
- Exchange
- SLSN NYSE
- NYXH Nasdaq
- Market Cap
- SLSN 270.6M
- NYXH 290.9M
- IPO Year
- SLSN N/A
- NYXH 2021
- Fundamental
- Price
- SLSN $2.78
- NYXH $7.31
- Analyst Decision
- SLSN
- NYXH Strong Buy
- Analyst Count
- SLSN 0
- NYXH 4
- Target Price
- SLSN N/A
- NYXH $14.50
- AVG Volume (30 Days)
- SLSN 74.6K
- NYXH 44.1K
- Earning Date
- SLSN 07-31-2025
- NYXH 08-18-2025
- Dividend Yield
- SLSN N/A
- NYXH N/A
- EPS Growth
- SLSN N/A
- NYXH N/A
- EPS
- SLSN 0.07
- NYXH N/A
- Revenue
- SLSN $64,417,000.00
- NYXH $4,716,818.00
- Revenue This Year
- SLSN N/A
- NYXH $209.22
- Revenue Next Year
- SLSN N/A
- NYXH $219.37
- P/E Ratio
- SLSN $45.92
- NYXH N/A
- Revenue Growth
- SLSN 65.67
- NYXH N/A
- 52 Week Low
- SLSN $1.21
- NYXH $5.55
- 52 Week High
- SLSN $16.56
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- SLSN N/A
- NYXH 43.37
- Support Level
- SLSN N/A
- NYXH $7.00
- Resistance Level
- SLSN N/A
- NYXH $7.59
- Average True Range (ATR)
- SLSN 0.00
- NYXH 0.33
- MACD
- SLSN 0.00
- NYXH -0.08
- Stochastic Oscillator
- SLSN 0.00
- NYXH 27.89
About SLSN SOLESENCE INC
Solesence Inc is a scientifically driven health care solutions company across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. The group is engaged in the beauty category that develops and manufactures clean, inclusive, mineral-based skincare and makeup products at the forefront of skin health. Its brands are Stress Defense, Kleair, and Bloom.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.